Skip to search formSkip to main contentSkip to account menu

CD30 Immunotoxin

Known as: Ber-H2 immunotoxin, anti CD30 immunotoxin, anti Ki-1 immunotoxin 
An immunotoxin composed of an anti-CD30 monoclonal antibody and a toxin moiety, which targets antigen-positive cells and causes cytotoxic activity… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Mesothelin-targeted immunotoxin RG7787 has synergistic anti-tumor activity when combined with taxanes
Recombinant immunotoxins (RITs) are antibody-based therapeutics that carry a toxin payload. The RG7787 RIT targets the cancer… 
2008
2008
Anti‐PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice
Expression of the prostate specific membrane antigen (PSMA) is highly restricted to prostate epithelial cells. Therefore, toxin… 
2007
2007
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors
MUC1 is a mucin family protein, overexpressed in more than 90% of breast cancers in an underglycosylated form, exposing the core… 
1999
1999
Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
We have generated a stable bivalent Fv molecule [(dsFv)2] of the anti-erbB2 monoclonal antibody e23 in which the V(H) and V(L… 
1999
1999
Phase I Study of B43-PAP Immunotoxin in Combination with Standard 4-Drug Induction for Patients with CD 19+ Acute Lymphoblastic Leukemia (ALL) in Relapse, A Children's Cancer Group Study
Phase I Study of B43-PAP Immunotoxin in Combination with Standard 4-Drug Induction for Patients with CD 19+ Acute Lymphoblastic… 
1998
1998
Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L…
We have compared the antileukemic activity of the investigational biotherapeutic agent B43-PAP to the antileukemic activities of… 
1994
1994
Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
The transplantation of the human T-cell acute lymphoblastic leukaemia (T-ALL) cell line HSB-2 into severe combined… 
1993
1993
Effects of the intermolecular toxin-monoclonal antibody linkage on the in vivo stability, immunogenicity and anti-leukemic activity of B43 (anti-CD19) pokeweed antiviral protein immunotoxin.
We have successfully constructed highly potent and selective anti-CD19 PAP immunotoxins using each of the three crosslinking… 
1990
1990
Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo.
1990
1990
Human antibody responses to components of the monoclonal antimelanoma antibody ricin A chain immunotoxin XomaZyme-MEL.
Human antibody responses to immunotoxin components were evaluated in 21 melanoma patients who were treated with XomaZyme-MEL, a… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)